Non-specific effects of the inactivated influenza vaccine. A test-negative study: The inactivated influenza vaccine and SARS-CoV-2 infections

Publication date

2024-05-31

Authors

Sellies, Anne Jasmijn
Knol, Mirjam J.
de Melker, Hester E.
Bruijning-Verhagen, P. C.J.L.ORCID 0000-0003-4105-9669ISNI 0000000419559955
de Boer, Annemarijn R.ORCID 0000-0003-4200-0917

Editors

Advisors

Supervisors

Document Type

Article

Collections

Open Access logo

License

taverne

Abstract

Background: Previous research suggested that the inactivated influenza vaccine (IIV) may protect against SARS-CoV-2 infection or a severe course of COVID-19. These findings were however based on cohort studies, that are prone to confounding by indication. We examined the association between IIV and SARS-Cov-2 infection in a Dutch population using a test-negative design. Methods: This test-negative case-control study was conducted in adults (≥60) who tested because of COVID-19 like symptoms at community SARS-CoV-2 testing locations in the Netherlands during the period of November 8th 2021-March 11th 2022. Information on receipt of IIV in October-November 2021 was routinely collected at each visit. Logistic regression was used to calculate unadjusted, partially (sex, age, education level) and fully adjusted (COVID-19 vaccination, IIV 2020) odds ratios (ORs) for receipt of IIV in SARS-CoV-2 positive versus negative subjects. Differential effects on SARS-CoV-2 risk by time since IIV were investigated by including an interaction term for calendar time: November 2021-January 2022 vs February-March 2022. Results: In total, 1,832 participants were included in the main analysis, of whom 336 (18.3 %) had a positive SARS-CoV-2 test. No significant association between IIV and SARS-CoV-2 infection was found; fully adjusted OR of 1.07 (95 % CI: 0.78–1.49). The interaction term for time periods was not significant (1.04 [95 % CI: 0.51–2.15], p = 0.91). Results were robust in sensitivity analyses. Conclusions: While earlier observational studies suggested a protective non-specific effect of IIV and SARS-CoV-2 infections, this smaller, but well controlled test-negative design study does not suggest an effect, either positive or negative. Larger test-negative design studies, or alternative designs such as the self-controlled case series design are needed to confirm these findings and provide more definite answers on the topic.

Keywords

Influenza vaccination, Non-specific effects, Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2) infection, Test-negative design, Taverne, Molecular Medicine, General Immunology and Microbiology, General Veterinary, Public Health, Environmental and Occupational Health, Infectious Diseases

Citation

Sellies, A J, Knol, M J, de Melker, H E, Bruijning-Verhagen, P C J L & de Boer, A R 2024, 'Non-specific effects of the inactivated influenza vaccine. A test-negative study : The inactivated influenza vaccine and SARS-CoV-2 infections', Vaccine, vol. 42, no. 15, pp. 3455-3460. https://doi.org/10.1016/j.vaccine.2024.04.044